Fluoroquinolones and rifampin combination in the backdrop of heteroresistant tuberculosis.

ABSTRACT: The impact of heteroresistance on tuberculosis (TB) treatment outcomes is unclear, as is the role of different rifampin and isoniazid exposures on developing resistance mutations. Hollow fiber system model of TB (HFS-TB) units were inoculated with drug-susceptible Mycobacterium tuberculosis (Mtb) and treated with isoniazid and rifampin exposure identified in a clinical trial as leading to treatment failure and acquired drug resistance. Systems were sampled for drug concentration measurements, estimation of total and drug-resistant Mtb, and small molecule overlapping reads (SMOR) analysis for the detection of heteroresistance. In the second HFS-TB study, systems were inoculated with an isoniazid-resistant clinical strain and treated with various combinations of isoniazi

SUBMITTER: Vogensen VB 

PROVIDER: S-EPMC11823603 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature